Debjit Chattopadhyay
Stock Analyst at Guggenheim
(3.34)
# 843
Out of 4,479 analysts
48
Total ratings
50%
Success rate
2.28%
Average return
Main Sectors:
Top Industries:
27 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | Assumes: Neutral | n/a | $53.12 | - | 1 | Jun 28, 2024 | |
| FOLD Amicus Therapeutics | Upgrades: Buy | $13 | $9.85 | +31.98% | 1 | May 14, 2024 | |
| DTIL Precision BioSciences | Initiates: Buy | $19 | $9.41 | +101.91% | 2 | Apr 30, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $445 → $450 | $473.78 | -5.02% | 4 | Apr 18, 2024 | |
| VYGR Voyager Therapeutics | Initiates: Buy | $22 | $7.59 | +189.86% | 1 | Mar 26, 2024 | |
| DYN Dyne Therapeutics | Maintains: Buy | $33 → $37 | $34.65 | +6.78% | 2 | Mar 7, 2024 | |
| PRME Prime Medicine | Maintains: Buy | $24 → $20 | $5.28 | +278.79% | 2 | Mar 5, 2024 | |
| KRYS Krystal Biotech | Maintains: Buy | $130 → $175 | $177.61 | -1.47% | 3 | Feb 27, 2024 | |
| NAMS NewAmsterdam Pharma Company | Initiates: Buy | $30 | $20.30 | +47.78% | 1 | Jan 18, 2024 | |
| SLNO Soleno Therapeutics | Assumes: Buy | $40 | $39.73 | +0.68% | 1 | Nov 21, 2023 | |
| BMRN BioMarin Pharmaceutical | Reiterates: Buy | $110 | $82.22 | +33.79% | 3 | Sep 13, 2023 | |
| CNTA Centessa Pharmaceuticals | Maintains: Buy | $9 → $10 | $8.77 | +14.03% | 2 | Aug 15, 2023 | |
| QURE uniQure | Reiterates: Buy | $53 | $4.01 | +1,221.70% | 3 | Feb 28, 2023 | |
| ALLO Allogene Therapeutics | Maintains: Buy | $43 → $29 | $2.16 | +1,242.59% | 1 | Nov 21, 2022 | |
| PASG Passage Bio | Maintains: Buy | $13 → $11 | $1.00 | +1,000.44% | 2 | Nov 11, 2022 | |
| RARE Ultragenyx Pharmaceutical | Upgrades: Buy | $50 | $40.96 | +22.07% | 2 | Oct 13, 2022 | |
| ALNY Alnylam Pharmaceuticals | Downgrades: Neutral | n/a | $247.61 | - | 1 | Jun 27, 2022 | |
| IONS Ionis Pharmaceuticals | Initiates: Buy | $64 | $45.14 | +41.78% | 1 | Mar 1, 2022 | |
| BEAM Beam Therapeutics | Initiates: Buy | $130 | $22.57 | +475.99% | 1 | Jan 5, 2022 | |
| TSHA Taysha Gene Therapies | Initiates: Buy | n/a | $2.16 | - | 1 | Dec 16, 2021 | |
| NTLA Intellia Therapeutics | Initiates: Buy | n/a | $22.15 | - | 1 | Oct 5, 2021 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | n/a | $154.20 | - | 4 | Aug 31, 2020 | |
| GLPG Galapagos NV | Downgrades: Neutral | n/a | $25.34 | - | 3 | Aug 24, 2020 | |
| ZYME Zymeworks | Reiterates: Buy | n/a | $8.40 | - | 1 | Mar 3, 2020 | |
| WVE Wave Life Sciences | Maintains: Buy | n/a | $5.22 | - | 1 | Jan 2, 2020 | |
| BOLD Boundless Bio | Maintains: Buy | n/a | $4.30 | - | 1 | Oct 12, 2018 | |
| AGIO Agios Pharmaceuticals | Downgrades: Neutral | n/a | $42.05 | - | 2 | Jun 26, 2017 |
CRISPR Therapeutics AG
Jun 28, 2024
Assumes: Neutral
Price Target: n/a
Current: $53.12
Upside: -
Amicus Therapeutics
May 14, 2024
Upgrades: Buy
Price Target: $13
Current: $9.85
Upside: +31.98%
Precision BioSciences
Apr 30, 2024
Initiates: Buy
Price Target: $19
Current: $9.41
Upside: +101.91%
Vertex Pharmaceuticals
Apr 18, 2024
Maintains: Buy
Price Target: $445 → $450
Current: $473.78
Upside: -5.02%
Voyager Therapeutics
Mar 26, 2024
Initiates: Buy
Price Target: $22
Current: $7.59
Upside: +189.86%
Dyne Therapeutics
Mar 7, 2024
Maintains: Buy
Price Target: $33 → $37
Current: $34.65
Upside: +6.78%
Prime Medicine
Mar 5, 2024
Maintains: Buy
Price Target: $24 → $20
Current: $5.28
Upside: +278.79%
Krystal Biotech
Feb 27, 2024
Maintains: Buy
Price Target: $130 → $175
Current: $177.61
Upside: -1.47%
NewAmsterdam Pharma Company
Jan 18, 2024
Initiates: Buy
Price Target: $30
Current: $20.30
Upside: +47.78%
Soleno Therapeutics
Nov 21, 2023
Assumes: Buy
Price Target: $40
Current: $39.73
Upside: +0.68%
BioMarin Pharmaceutical
Sep 13, 2023
Reiterates: Buy
Price Target: $110
Current: $82.22
Upside: +33.79%
Centessa Pharmaceuticals
Aug 15, 2023
Maintains: Buy
Price Target: $9 → $10
Current: $8.77
Upside: +14.03%
uniQure
Feb 28, 2023
Reiterates: Buy
Price Target: $53
Current: $4.01
Upside: +1,221.70%
Allogene Therapeutics
Nov 21, 2022
Maintains: Buy
Price Target: $43 → $29
Current: $2.16
Upside: +1,242.59%
Passage Bio
Nov 11, 2022
Maintains: Buy
Price Target: $13 → $11
Current: $1.00
Upside: +1,000.44%
Ultragenyx Pharmaceutical
Oct 13, 2022
Upgrades: Buy
Price Target: $50
Current: $40.96
Upside: +22.07%
Alnylam Pharmaceuticals
Jun 27, 2022
Downgrades: Neutral
Price Target: n/a
Current: $247.61
Upside: -
Ionis Pharmaceuticals
Mar 1, 2022
Initiates: Buy
Price Target: $64
Current: $45.14
Upside: +41.78%
Beam Therapeutics
Jan 5, 2022
Initiates: Buy
Price Target: $130
Current: $22.57
Upside: +475.99%
Taysha Gene Therapies
Dec 16, 2021
Initiates: Buy
Price Target: n/a
Current: $2.16
Upside: -
Intellia Therapeutics
Oct 5, 2021
Initiates: Buy
Price Target: n/a
Current: $22.15
Upside: -
Sarepta Therapeutics
Aug 31, 2020
Maintains: Buy
Price Target: n/a
Current: $154.20
Upside: -
Galapagos NV
Aug 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $25.34
Upside: -
Zymeworks
Mar 3, 2020
Reiterates: Buy
Price Target: n/a
Current: $8.40
Upside: -
Wave Life Sciences
Jan 2, 2020
Maintains: Buy
Price Target: n/a
Current: $5.22
Upside: -
Boundless Bio
Oct 12, 2018
Maintains: Buy
Price Target: n/a
Current: $4.30
Upside: -
Agios Pharmaceuticals
Jun 26, 2017
Downgrades: Neutral
Price Target: n/a
Current: $42.05
Upside: -